Tempest Therapeutics Unveils New Stock Option Grants
Tempest Therapeutics, Inc. (Nasdaq: TPST), an innovative biotechnology firm based in California, continues to push the boundaries in the battle against cancer with its groundbreaking therapeutics. Recently, the company has taken a major step forward by granting nonqualified stock options to two employees as part of its 2023 Inducement Plan. This move underscores Tempest's dedication to attracting and retaining skilled personnel in a highly competitive sector.
Stock Option Grant Details
The Compensation Committee at Tempest Therapeutics has officially approved the distribution of 79,500 stock options. These options are structured to vest over a four-year timeline. Initially, 25% will be accessible on the anniversary of the employee's first year with the company, with the remaining options vesting on a monthly basis thereafter. This plan not only fosters long-term commitment but also aligns employees’ interests with the overall success of the company.
Understanding the Vesting Schedule
The structure of the vesting schedule promotes employee retention and loyalty. Each month, following the first anniversary, 1/48th of the stock options will become exercisable, contingent upon the employee's ongoing tenure at Tempest. This strategy effectively motivates employees to make valuable contributions to the company’s progress and growth.
About Tempest Therapeutics
Established to lead in the biotech industry, Tempest Therapeutics is dedicated to creating cutting-edge therapeutics designed to treat various types of cancer. Their portfolio includes a wide range of small molecule product candidates that focus on tumor-targeting and immune-mediated mechanisms. The company is currently progressing through advanced clinical trials, including a crucial global study targeting first-line cancer patients.
Advancements in Research and Development
Tempest is not just making headway with early-phase research; it is also achieving significant milestones in later-stage investigations. This commitment reflects its mission to bring impactful treatments to market, enhancing the potential to transform options for cancer therapy.
Contact Information for Investor Relations
If you have any questions, investors and media contacts can reach out to the following individuals:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Frequently Asked Questions
What is the purpose of the stock options granted by Tempest Therapeutics?
The stock options are designed to attract and maintain skilled employees while ensuring their interests are aligned with the company’s success.
How many stock options were issued to employees under this plan?
A total of 79,500 stock options have been granted to two employees as part of the 2023 Inducement Plan.
Can you explain the vesting schedule for these stock options?
The stock options vest in two stages: 25% on the employee's first anniversary and then 1/48th on a monthly basis thereafter.
What kinds of therapeutics does Tempest Therapeutics focus on?
Tempest Therapeutics specializes in targeted and immune-mediated therapies aimed at addressing a variety of cancer types.
Who should I contact for further information on Tempest's investor relations?
You can reach out to Sylvia Wheeler or Aljanae Reynolds through their email addresses provided above.
